Walvax Biotechnology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Walvax Biotechnology's earnings have been declining at an average annual rate of -10.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 19.3% per year. Walvax Biotechnology's return on equity is 1.4%, and it has net margins of 4%.
Belangrijke informatie
-10.6%
Groei van de winst
-11.6%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.3% |
Inkomstengroei | 19.3% |
Rendement op eigen vermogen | 1.4% |
Nettomarge | 4.0% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S
Sep 24Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares
May 23There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Opbrengsten en kosten
Hoe Walvax Biotechnology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 3,097 | 122 | 1,337 | 621 |
30 Jun 24 | 3,379 | 135 | 1,597 | 687 |
31 Mar 24 | 3,880 | 262 | 1,787 | 672 |
31 Dec 23 | 4,114 | 419 | 1,868 | 763 |
30 Sep 23 | 4,538 | 751 | 2,025 | 818 |
30 Jun 23 | 4,906 | 763 | 2,206 | 885 |
31 Mar 23 | 5,264 | 862 | 2,353 | 962 |
01 Jan 23 | 5,086 | 729 | 2,301 | 922 |
30 Sep 22 | 5,040 | 595 | 2,320 | 958 |
30 Jun 22 | 4,461 | 530 | 2,011 | 827 |
31 Mar 22 | 3,685 | 434 | 1,729 | 704 |
01 Jan 22 | 3,463 | 428 | 1,631 | 616 |
30 Sep 21 | 3,501 | 932 | 1,575 | 355 |
30 Jun 21 | 3,715 | 1,261 | 1,670 | 311 |
31 Mar 21 | 3,260 | 1,053 | 1,473 | 212 |
31 Dec 20 | 2,939 | 1,003 | 1,345 | 174 |
30 Sep 20 | 1,890 | 457 | 1,000 | 174 |
30 Jun 20 | 1,194 | 119 | 699 | 82 |
31 Mar 20 | 1,057 | 85 | 685 | 62 |
31 Dec 19 | 1,121 | 142 | 660 | 63 |
30 Sep 19 | 1,098 | 1,444 | 557 | 75 |
30 Jun 19 | 1,000 | 1,426 | 541 | 95 |
31 Mar 19 | 933 | 1,430 | 412 | 135 |
31 Dec 18 | 874 | 1,415 | 418 | 138 |
30 Sep 18 | 807 | -407 | 504 | 127 |
30 Jun 18 | 786 | -421 | 399 | 166 |
31 Mar 18 | 700 | -484 | 432 | 111 |
31 Dec 17 | 668 | -537 | 439 | 94 |
30 Sep 17 | 628 | 265 | 276 | 72 |
30 Jun 17 | 555 | 189 | 345 | 0 |
31 Mar 17 | 466 | 83 | 358 | 0 |
31 Dec 16 | 591 | 70 | 375 | 0 |
30 Sep 16 | 692 | -963 | 641 | 0 |
30 Jun 16 | 885 | -936 | 659 | 0 |
31 Mar 16 | 1,045 | -835 | 622 | 0 |
31 Dec 15 | 1,006 | -841 | 624 | 0 |
30 Sep 15 | 843 | 182 | 527 | 0 |
30 Jun 15 | 731 | 138 | 557 | 0 |
31 Mar 15 | 705 | 147 | 550 | 0 |
31 Dec 14 | 719 | 143 | 554 | 0 |
30 Sep 14 | 816 | -139 | 469 | 0 |
30 Jun 14 | 750 | -91 | 433 | 0 |
31 Mar 14 | 676 | -29 | 391 | 0 |
31 Dec 13 | 583 | 48 | 355 | 0 |
Kwaliteitswinsten: 300142 has a large one-off loss of CN¥120.5M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 300142's current net profit margins (4%) are lower than last year (16.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 300142's earnings have declined by 10.6% per year over the past 5 years.
Versnelling van de groei: 300142's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 300142 had negative earnings growth (-83.7%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Rendement op eigen vermogen
Hoge ROE: 300142's Return on Equity (1.4%) is considered low.